Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,570,288
  • Shares Outstanding, K 153,882
  • Annual Sales, $ 14,378 M
  • Annual Income, $ 5,889 M
  • 60-Month Beta 0.61
  • Price/Sales 2.61
  • Price/Cash Flow 6.32
  • Price/Book 3.49
Trade BIIB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 5.12
  • Number of Estimates 28
  • High Estimate 7.60
  • Low Estimate 4.15
  • Prior Year 8.34
  • Growth Rate Est. (year over year) -38.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
223.25 +9.02%
on 11/09/20
363.92 -33.12%
on 11/04/20
-21.62 (-8.16%)
since 10/23/20
3-Month
223.25 +9.02%
on 11/09/20
363.92 -33.12%
on 11/04/20
-33.69 (-12.16%)
since 08/21/20
52-Week
223.25 +9.02%
on 11/09/20
374.99 -35.10%
on 02/05/20
-55.70 (-18.62%)
since 11/22/19

Most Recent Stories

More News
DEADLINE FOR BIIB INVESTORS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.

New York, New York--(Newsfile Corp. - November 23, 2020) -  Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a...

BIIB : 243.38 (-0.32%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PT, BTU and BIIB

NEW YORK, NY / ACCESSWIRE / November 23, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies....

PT : 0.9198 (+4.52%)
BTU : 1.3700 (+17.09%)
BIIB : 243.38 (-0.32%)
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Biogen, Inc. ("Biogen" or the "Company") (NASDAQ:...

BIIB : 243.38 (-0.32%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 12, 2021 - BIIB

New York, New York--(Newsfile Corp. - November 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

BIIB : 243.38 (-0.32%)
BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Investors of Class Action and Encourages Investors to Contact the Firm

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain of its officers, on behalf of...

BIIB : 243.38 (-0.32%)
LAWSUITS FILED AGAINST TRQ, RTX and BIIB - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

TRQ : 10.56 (+1.64%)
RTX : 72.64 (+4.13%)
BIIB : 243.38 (-0.32%)
ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment

, /PRNewswire/ -- ISD Immunotech (ISD), which is developing targeted therapies for severe autoimmune diseases, today announces it has entered into a strategic research collaboration with Biogen Inc.,...

BIIB : 243.38 (-0.32%)
ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm - BIIB

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the "Class Period") of the...

BIIB : 243.38 (-0.32%)
BIOGEN INVESTOR ALERT: SHAREHOLDER LAWSUIT FILED

Boston, Massachusetts--(Newsfile Corp. - November 22, 2020) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Biogen Inc. (NADSAQ: BIIB). Investors...

BIIB : 243.38 (-0.32%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...

BIIB : 243.38 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 247.96
1st Resistance Point 245.67
Last Price 243.38
1st Support Level 241.13
2nd Support Level 238.88

See More

52-Week High 374.99
Fibonacci 61.8% 317.03
Fibonacci 50% 299.12
Fibonacci 38.2% 281.21
Last Price 243.38
52-Week Low 223.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar